BioSpace News Archive

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a strategic collaboration with Fox Chase Cancer Center in Philadelphia for the PGDx elio™ plasma resolve liquid biopsy panel.

Pear Therapeutics Announces Publication of Economic Analysis Showing Cost-Effectiveness of reSET-O ® in Treating Opioid Use Disorder reSET-O ® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD).

UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in March 2021: Cowen 41 st Annual Health Care Conference

Masimo (NASDAQ: MASI) today announced the U.S. introduction of softFlow®, innovative pulmonary care therapy which provides nasal high-flow warmed and humidified respiratory gases to spontaneously breathing patients

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Andrew King, D.V.M., Ph.D., Head of Renal Discovery and Translational Medicine, will present on behalf of Chinook at the 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit.

908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it has appointed Jeff George and Fenel Eloi to serve on its Board of Directors,

Vystar® Corporation (OTCQB: VYST) has named Byron Novosad, DDS, to the Vystar Board of Directors, effective immediately.

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021.

From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are spending approximately 13 hours a day on some type of digital device.1 As the reliance on screens to connect digitally for both professional and personal use continues to rise, more than half of adults suffer from digital eye strain,2 which often includes dry, irritated eyes.

Newronika, a spin-off of the world-class neurological research center Policlinico of Milan and University of Milan, announced today it received CE Mark approval for its AlphaDBS System.